FR2519549A1 - Medicaments a base de nitroglycerine pour le traitement de l'insuffisance coronarienne et de l'insuffisance cardiaque - Google Patents
Medicaments a base de nitroglycerine pour le traitement de l'insuffisance coronarienne et de l'insuffisance cardiaque Download PDFInfo
- Publication number
- FR2519549A1 FR2519549A1 FR8200223A FR8200223A FR2519549A1 FR 2519549 A1 FR2519549 A1 FR 2519549A1 FR 8200223 A FR8200223 A FR 8200223A FR 8200223 A FR8200223 A FR 8200223A FR 2519549 A1 FR2519549 A1 FR 2519549A1
- Authority
- FR
- France
- Prior art keywords
- nitroglycerin
- nitroglycerine
- coronary
- contg
- ointments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 229960003711 glyceryl trinitrate Drugs 0.000 title claims abstract description 17
- 239000000006 Nitroglycerin Substances 0.000 title claims description 13
- 239000002674 ointment Substances 0.000 title abstract description 5
- 206010052895 Coronary artery insufficiency Diseases 0.000 title abstract description 4
- 206010019280 Heart failures Diseases 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 206010024119 Left ventricular failure Diseases 0.000 abstract description 12
- 208000010125 myocardial infarction Diseases 0.000 abstract description 3
- 206010019233 Headaches Diseases 0.000 abstract description 2
- 231100000869 headache Toxicity 0.000 abstract description 2
- 230000002489 hematologic effect Effects 0.000 abstract description 2
- 230000002440 hepatic effect Effects 0.000 abstract description 2
- 210000000115 thoracic cavity Anatomy 0.000 abstract description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- AKIJONGZTGVCPH-UHFFFAOYSA-N 4-phenoxypyridine-2,6-diamine Chemical compound NC1=NC(N)=CC(OC=2C=CC=CC=2)=C1 AKIJONGZTGVCPH-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 206010049813 Non-obstructive cardiomyopathy Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000016569 congenital mitral valve insufficiency Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8200223A FR2519549A1 (fr) | 1982-01-08 | 1982-01-08 | Medicaments a base de nitroglycerine pour le traitement de l'insuffisance coronarienne et de l'insuffisance cardiaque |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8200223A FR2519549A1 (fr) | 1982-01-08 | 1982-01-08 | Medicaments a base de nitroglycerine pour le traitement de l'insuffisance coronarienne et de l'insuffisance cardiaque |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2519549A1 true FR2519549A1 (fr) | 1983-07-18 |
| FR2519549B3 FR2519549B3 (cg-RX-API-DMAC10.html) | 1985-02-08 |
Family
ID=9269820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8200223A Granted FR2519549A1 (fr) | 1982-01-08 | 1982-01-08 | Medicaments a base de nitroglycerine pour le traitement de l'insuffisance coronarienne et de l'insuffisance cardiaque |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2519549A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1319613C (en) * | 1986-10-07 | 1993-06-29 | Gevork Minaskanian | Penetration enhancers for transdermal delivery of systemic agents |
-
1982
- 1982-01-08 FR FR8200223A patent/FR2519549A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2519549B3 (cg-RX-API-DMAC10.html) | 1985-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kernoff et al. | Antithrombotic potential of dihomo-gamma-linolenic acid in man. | |
| US8519005B2 (en) | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy | |
| Zusman et al. | The effect of chronic sodium loading and sodium restriction on plasma prostaglandin A, E and F concentrations in normal humans | |
| Kangasniemi et al. | Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study | |
| BE901994A (fr) | Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage. | |
| FR2774591A1 (fr) | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie | |
| BE899885A (fr) | Comprimes de naproxen et de naproxen sodique a liberation controlee. | |
| Rajatanavin et al. | Five patients with iodine-induced hyperthyroidism | |
| WO2012009545A1 (en) | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists | |
| Amandi-Burgermeister et al. | Suppression of cytokine synthesis, integrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A2 | |
| Somogyi | Diabetogenic effect of hyperinsulinism | |
| Ogryzlo et al. | Evaluation of uricosuric agents in chronic gout | |
| Rasmussen et al. | Choreoathetosis during phenytoin treatment | |
| EP0117163B1 (fr) | Dispositif endo-utérin contraceptif et thérapeutique combinant le cuivre, la progestérone naturelle et l'acide amino iso caproique | |
| RU2095064C1 (ru) | Средство для снижения агрегации тромбоцитов в кровеносной системе | |
| CANTU et al. | Ceruloplasmin rise and PBI fall in serum due to diphenylhydantoin | |
| ITMI950532A1 (it) | Derivato di aminotetralina per la terapia di malattie cardiovascolari | |
| BE1002182A5 (fr) | Compositions pharmaceutiques. | |
| US5200428A (en) | Agent for the tsh suppression and treatment of struma | |
| JPS62190130A (ja) | エイズウイルス性疾患処置剤 | |
| EP0760241B1 (fr) | Utilisation de la sulfasalazine et/ou de son métabolite actif pour la fabrication d'un médicament utile dans le traitement de l'insuffisance veineuse et des ulcères veineux | |
| KAUFMAN et al. | Bumetanide‐Induced Diuresis and Natriuresis: Effect of Prostaglandin Synthetase Inhibition | |
| Tan et al. | Sodium intake as a determinant of urinary prostaglandin E2 excretion | |
| Westermark et al. | Nodular goiter: effects of surgery and thyroxine medication | |
| Zatarain et al. | Rhabdomyolysis and acute renal failure associated with lovastatin |